How we work

We constantly push ourselves in the pursuit of better – better solutions, better processes and better ways of working that help our clients navigate complexity and make better decisions with greater confidence

The Journey

We recognize that the journey is often as important as the destination. We work like an extension of your team so your overall journey with us feels better

The Journey

Our Values

Our culture is founded on a strong set of values that guide how we work with each other and our clients. We are a PASSIONATE team who believe in COLLABORATIVE SPIRIT and a CAN-DO attitude. We build BOLD solutions and make insightful recommendations because we dig deeper and remain CONSTANTLY CURIOUS, to provide positive challenge and FRESH THINKING

Our Values

Solving unique problems

Whether we are supporting you on your journey, or delivering specialist expertise, we are helping you make important choices

With a global perspective

We work with 24 of the top 25 pharmaceutical companies as well as 100s of Biotechs globally from our offices in the US and Europe

Our locations

Teams of experts

We are expert navigators helping guide our clients to more successful outcomes

Expert Navigation

Explore case studies that bring to life how we’ve uncovered hidden insights, explored scientific options and helped make difficult strategic choices

Case studies
TCR T-cell Therapies: What if Magic Bullets Simply Aren't Good Enough?
TCR T-cell Therapies: What if Magic Bullets Simply Aren't Good Enough?
On the heels of a recent post in which I discussed evolving dynamics and strategic implications underscoring different types of allogeneic cell therapies in oncology, I find it fitting to address another substantive consideration in the field, that of targeting moieties.
Donor-derived T-cells vs. iPSC- and Cord-derived NKs: Allo Not Created Equal
Donor-derived T-cells vs. iPSC- and Cord-derived NKs: Allo Not Created Equal
A common question I get from my cancer cell therapy clients at Cello Health BioConsulting is why, despite the lion share of clinical data in support of T-cell therapies, it is NK cell therapy candidates (iPSC- and cord-derived) that seem of late to be capturing so much more enthusiasm from investors and Pharma these days?The answer has to do in large part with the risk-averse nature of Pharma, which in this case has been laudable.
Different perspectives on the Burden of Disease
Different perspectives on the Burden of Disease
What do medical market research and health economic outcomes research have in common? How can we combine our work on burden of disease in a way which realises it fullest potential? What can we learn from each other’s approach?Our starting pointAs we became acquainted with the work of our colleagues in the Health Economic Outcomes research world, we came to realise that we overlapped in areas of research with patients, but that in other fundamental ways we were differing – for example in our.
Are We Nearing the Plateau of Productivity for in-vivo Therapeutic Gene Editing?
Are We Nearing the Plateau of Productivity for in-vivo Therapeutic Gene Editing?
Amidst success of in vivo adeno-associated virus (AAV) based gene therapies, the gene therapy community awaits key outcomes from next month’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) meeting discussing toxicities and deaths associated with high titer AAV dosing and potential long-term adverse events.